Novo Nordisk defended disappointing trial results for its obesity drug candidate CagriSema, emphasizing its importance as a weight loss treatment despite underwhelming outcomes in late-stage trials. CEO Lars Fruergaard Jørgensen acknowledged the share price impact but expressed confidence in CagriSema’s potential, reassuring shareholders at the Annual General Meeting in Copenhagen, Denmark that it will be a significant product for the company.
Full Article
Rotorua man charged with abducting 3-year-old from daycare for sex
SummaryJohn Tekuru, a 19-year-old, appeared in the Rotorua District Court charged with abducting a 3-year-old girl from a local early childhood center for sexual purposes. He did not enter a plea to the charge of unlawfully taking the girl on March 10 and has been remanded in custody until his next court appearance on May 14. Judge Joanne Wickliffe granted permanent name suppression for the daycare center to protect the identity of the victim. Full...
Read more